Leadership Team

Leadership Team

Our Leadership Team has a broad range of experience and is responsible for managing the business on a day‑to‑day basis.

  • Dame Louise Makin

    Chief Executive Officer

    Dame Louise Makin, MA, PhD (Cantab), MBA, DBE, joined BTG as Chief Executive Officer in October 2004. She is a non-executive director of Intertek Group plc and the Woodford Patient Capital Trust, a Trustee of the Outward Bound Trust and an Honorary Fellow of St. John’s College, Cambridge.

    From 2001, she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe. Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998.

    Show moreShow less
  • Rolf Soderstrom

    Chief Financial Officer

    Rolf Soderstrom, BA, ACA, joined BTG as Chief Financial Officer in December 2008 from Protherics PLC, where he was Finance Director from August 2007.

    From 2004, he was a Divisional Finance Director of Cobham plc, managing a portfolio of businesses across Europe and the USA. From 2000 he was a Director of Corporate Finance at Cable & Wireless plc. Prior to this, he worked in the Corporate Recovery and Corporate Finance Department of PricewaterhouseCoopers after qualifying as a Chartered Accountant.

    Show moreShow less
  • Guenter R. Janhofer

    Chief Medical Officer

    Guenter R Janhofer joined BTG in March 2009 as Head of Development. In 2011 he also became BTG's Chief Medical Officer. Guenter has more than 25 years of experience in the pharmaceutical industry across all phases of clinical development from Phase I to end-stage life-cycle management and across a wide variety of therapeutic areas, including cardiovascular, metabolic, neuroscience, infectious diseases, respiratory, osteoporosis and oncology.

    Having started as Medical Director of Desitin Pharmaceuticals in Hamburg, Germany, he later served Merck & Co., Inc. in functions of growing complexity and scope, both at the subsidiary and at the headquarters’ level. He most recently served as Vice President of Global Medical and Scientific Affairs and has been instrumental of bringing Internet technology to Merck’s clinical development process. Guenter holds an MD degree from Hamburg University, PhDs in Climatology and Medicine from the University of Bochum and a post-doc degree (Habilitation) from the University of Technology in Berlin, where he is a faculty member at the School of Public Health.

    Show moreShow less
  • Melanie Lee

    Chief Scientific Officer

    Melanie Lee, PhD, CBE, FMedSci, DSc (Hons), became BTG’s Chief Scientific Officer in November 2014 having previously served as a non-Executive Director at the company since November 2010.

    Melanie is the Chief Executive Officer of NightstaRx Ltd, a Founder and Director of the pharmaceutical consultancy Think10, and a non-executive director of H Lundbeck A/S. Melanie was previously CEO of Syntaxin Ltd until it was sold to Ipsen, she was the Chair of Cancer Research Technology and a Trustee and Deputy-Chair of Cancer Research UK. During her career Melanie has held a number of positions at Glaxo, GlaxoWellcome, Celltech and UCB. In 2008, Melanie was honoured with a CBE for her services to Medical Science.

    Show moreShow less
  • John Sylvester

    Corporate Development Officer

    John Sylvester joined BTG in January 2011, following the acquisition of Biocompatibles. John joined Biocompatibles in 2005 and was appointed to the Board in the same year.

    His career covers a series of commercial roles for Rio Tinto Zinc plc, ICI plc and English China Clays where he was General Manager for their European and Asian Operations. Previously he was with Baxter Healthcare where he was VP Marketing for their European Medication delivery business.

    Show moreShow less
  • Paul Mussenden

    General Counsel, Head of Strategic Affairs
    Company Secretary

    Joining BTG in 2000, Paul has over 20 years’ experience advising companies in the healthcare industry at all stages of development. He is General Counsel, Head of Strategic Affairs & Company Secretary.

    As a member of the executive Leadership Team Paul is accountable for the Legal, Regulatory, Intellectual Property, Healthcare Compliance and Risk Management functions. He has extensive experience of supporting the establishment of corporate governance & risk management frameworks; Corporate Finance; Mergers & Acquisitions (private & public); fundraisings and investment (equity, private equity & debt); IP licensing & business development; supporting drug and medical device research, development, manufacturing & commercialization; complex litigation and dispute resolution.

    Paul has a BSc(Hons) in Biotechnology and a Ph.D in molecular biology and microbial physiology. Having qualified as a solicitor with Norton Rose Fulbright before joining BTG, Paul focused for a number of years in the area of corporate finance and corporate development before moving to the Equity Markets Group of the London Stock Exchange focusing on healthcare company transactions.

    Paul is also a non-executive director and trustee of the charity Medical Research Council Technologies, a business focused on the translation of R&D innovation into commercial products to better human health.

    Show moreShow less
  • Yvonne Rogers

    Head of Human Resources

    Yvonne Rogers joined BTG in December 2008 following the merger of BTG and Protherics. She joined Protherics in November 2003 to build Protherics’ Human Resources and Learning and Development activities across the global company. Since April 2010 she has taken on global responsibility for IT.

    Before joining Protherics she held senior roles at Troika UK Limited, KPMG, The Mitsubishi Bank and House of Fraser. A graduate of the Chartered Institute of Personnel and Development, she has spent over 20 years as a generalist Human Resources professional.

    Show moreShow less
  • Peter Stratford

    Head of Innovation

    Peter Stratford joined BTG in January 2011, following the acquisition of Biocompatibles. Peter joined Biocompatibles in 1990 and was appointed to the Board in 2002. He took the role of Group Director Research and Development in 1998 and transitioned the Group to the current oncology products focus.

    He joined the Cardiovascular Division Management Team at its creation in 1993, after completion of development work in contact lens application. Peter has a BSc in Chemistry, an MSc in Polymer Synthesis and a PhD in Pharmaceutical Synthesis.

    Show moreShow less
  • Duncan Kennedy

    Head of Interventional Oncology

    Duncan Kennedy joined BTG in December 2005 as Group Financial Controller and joined the Leadership Team in April 2012 following appointment to his current role. He has management responsibility for the global finance function, supporting the CFO, and was a member of the acquisition and subsequent integration teams for the acquisitions of Protherics PLC in 2008 and Biocompatibles International plc in 2011.

    Prior to joining BTG, Duncan spent six years in the group finance function of Wembley plc, an international leisure group, gaining wide-ranging experience in all aspects of listed company financial reporting and significant involvement in corporate transactions. Duncan qualified as a Chartered Accountant at Arthur Andersen and holds a BSc in Mathematics from Durham University.

    Show moreShow less
  • Anthony Higham

    Head of Manufacturing & Supply
    Head of US Commercial Operations

    Anthony Higham joined BTG in January 2011 with responsibility for leading all manufacturing operations across global sites in the USA, Australia and the UK. He joins following a period spent as an independent industry consultant.

    He has previously held a number of international, senior Operational and Site Leadership roles at SmithKline Beecham, GlaxoSmithKline and Aesica Pharmaceuticals. Anthony has a BSc in Biological Sciences from Bangor University and an MSc in Manufacturing Systems Engineering from Hatfield Polytechnic.

    Show moreShow less
  • Paul McCubbin

    Head of Strategy

    Paul McCubbin, MA, D Phil, ACA, joined BTG in 2001, working initially in the Corporate Venturing team and became head of that business unit in 2004. Since then he has taken on a succession of operational roles at BTG. In 2009 he was appointed General Manager of Varithena®, and became the Head of Varithena® in April 2013, following submission of a new drug application for the product in the US.

    Varithena® received FDA approval in November 2013 for the treatment for patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. Prior to joining BTG, Paul was the Finance Director of Profiad Limited, a CRO spun-out of GlaxoWellcome. Previously, he led the corporate finance team in Ernst & Young’s life sciences group, advising early stage companies on strategy, partnering and fundraising. Paul qualified as a chartered accountant in 1995, whilst working in the corporate recovery and turnaround divisions at Arthur Andersen. Paul gained his degree and doctorate in biological sciences from the University of Oxford and worked as an MRC post-doctoral research fellow at Manchester University.

    Show moreShow less
  • Our History

    We have a rich heritage spanning many decades, from our commercialisation of intellectual property to our transformation into a specialist healthcare company.

    Read more
  • Governance

    Our Code of Conduct has been developed to promote ethical behaviour from all our employees and is based on our foundation of core company values.

    Read more